α-Melanocyte Stimulating Hormone [Met5, Pro6, D-Phe7, D-Trp9, Phe10] (5-13) (MSHa)

The mechanism of action involves binding to melanocortin receptors (primarily MC1R, MC3R, MC4R, and MC5R) with high affinity, acting as either an agonist or antagonist depending on the receptor subtype and experimental context. Receptor engagement activates Gαs protein-coupled signaling pathways, leading to intracellular cAMP accumulation and subsequent downstream effects including melanin synthesis in melanocytes, appetite regulation in the central nervous system, and modulation of inflammatory responses. The specific amino acid modifications (D-Phe7, D-Trp9, and other substitutions) enhance receptor selectivity, increase resistance to enzymatic degradation, and prolong biological activity compared to the native peptide, making it a more potent and stable research tool for dissecting melanocortin receptor functions.

This MSHa peptide is indicated for research use only in preclinical studies investigating melanocortin receptor biology, skin pigmentation mechanisms, obesity and metabolic disorders, sexual function, and inflammatory processes. It serves as a standard pharmacological tool in receptor binding assays, functional assays measuring cAMP production or calcium mobilization, and animal models of pigmentation disorders, appetite regulation, and metabolic syndrome. The product is also used in structure-activity relationship studies to understand ligand-receptor interactions and in the development of novel therapeutic compounds targeting melanocortin pathways. It is not intended for diagnostic, therapeutic, or clinical applications in humans or animals.

As a research reagent, α-Melanocyte Stimulating Hormone [Met5, Pro6, D-Phe7, D-Trp9, Phe10] (5-13) (MSHa) does not have established clinical efficacy for therapeutic use in human patients. While this peptide analog and related compounds have been studied in preclinical models to understand melanocortin receptor physiology and potential therapeutic applications, the product itself has not undergone clinical development or received regulatory approval for any medical indication. Research using this peptide has contributed to the understanding of melanocortin signaling pathways and the identification of potential drug targets, but the product remains an investigational research tool without proven clinical efficacy or safety profile for human use.